Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences
Published in: Digestive Diseases and Sciences 1/2007

01-01-2007 | Letter to the Editor

Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab

Authors: Masaru Odashima, Michiro Otaka, Mario Jin, Youhei Horikawa, Tamostu Matsuhashi, Reina Ohba, Shigeto Koizumi, Nobukatsu Kinoshita, Taiji Takahashi, Sumio Watanabe

Published in: Digestive Diseases and Sciences | Issue 1/2007

Login to get access

Excerpt

Since the introduction of the anti-tumor necrosis factor (TNF) monoclonal antibody infliximab 1997, the treatment of Crohn’s disease has changed dramatically [1]. Duodenal Crohn’s disease is rare and unique in that its clinical response to medical therapy is universally poor and usually requires surgical therapy such as gastrojejunal bypass [2]. We present one case of duodenal Crohn’s disease with severe stricture that was resolved by treatment with infliximab. …
Literature
1.
Targan SR, Hanauer SB, Van Deventer SJ, Mayer L, Present DH, Braakman T, DeWoody KL, Schible TF, Rutgeerts PJ (1997) A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med 337:1029–1035CrossRefPubMed
2.
Nugent WF, Roy MZ (1986) Duodenal Crohn’s disease: an analysis of 89 cases. Am J Gastroenterol 89:249–254
3.
D’Haens G, Van Deventer SJ, Van Hoegezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P (1999) Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: A European multicenter trial. Gastroenterology 116:1029–1034CrossRefPubMed
4.
DiSabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR (2004) Infliximab down-regulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn’s disease patients. Aliment Pharmacol Ther 19:1019–1024CrossRef
Metadata
Title
Successful Treatment of Refractory Duodenal Crohn’s Disease with Infliximab
Authors
Masaru Odashima
Michiro Otaka
Mario Jin
Youhei Horikawa
Tamostu Matsuhashi
Reina Ohba
Shigeto Koizumi
Nobukatsu Kinoshita
Taiji Takahashi
Sumio Watanabe
Publication date
01-01-2007
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 1/2007
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-006-9585-3

Other articles of this Issue 1/2007

Digestive Diseases and Sciences 1/2007 Go to the issue

Original Paper

Hyperplastic Polyps of the Gastric Antrum in Patients with Gastrointestinal Blood Loss

Original Article

Oral Carbohydrate Solution Ameliorates Endotoxemia-Induced Splanchnic Ischemia

Original Paper

Amifostine (Wr-2721) Prevents Indomethacin-Induced Gastric Damage in Rats: Role of Non-Protein Sulfhydryl Groups and Leukocyte Adherence

Original Article

Acute Hemorrhage Following Transhepatic PEG Tube Placement

Original Paper

Evidence of a Genetic Basis for the Different Geographic Occurrences of Liver/Kidney Microsomal Antibody Type 1 in Hepatitis C

Original Paper

The Effect of Oral α-Galactosidase on Intestinal Gas Production and Gas-Related Symptoms
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits